Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for oxaliplatin-induced neuropathy
IRCT20150726023349N5Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in chemotherapy-induced peripheral neuropathy (CIPN) and peripheral neuropathy (CIPN), sponsored by Tehran University of Medical Sciences. Primary endpoint: Improvement in oxaliplatin-induced neuropathy. Started Sep 2022; status: completed.
02
Drugs
melatonin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20150726023349N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150726023349N5.